Newborn screening for fragile X syndrome

Area of Science:

• Genetics
• Public Health
• Genomic Medicine

Background:

• Fragile X syndrome (FXS) results from FMR1 gene CGG repeat expansion (>200 repeats).
• Current US newborn screening (NBS) panels do not include FXS due to unmet recommendation standards.
• Advances in genomic testing and FXS treatments challenge traditional NBS principles.

Purpose of the Study:

• To evaluate the feasibility and implications of including Fragile X syndrome in newborn screening programs.
• To discuss the arguments for and against population-based screening for FXS.
• To address the ethical and practical challenges associated with NBS for FXS and its carriers.

Main Methods:

• Review of current NBS criteria and feasibility studies for FXS.
• Analysis of benefits (early intervention, family counseling) versus challenges (psychosocial burden, carrier identification).
• Discussion of ethical considerations, informed consent, and necessary infrastructure for NBS implementation.

Main Results:

• FXS screening is technically feasible and offers potential benefits for early intervention and family planning.
• Significant ethical and psychosocial challenges exist, particularly regarding the identification of premutation carriers and their health risks.
• The debate on FXS NBS remains open, emphasizing the need for careful consideration of all implications.

Conclusions:

• Implementing NBS for FXS requires robust infrastructure for testing, counseling, and treatment.
• Informed parental consent and awareness of potential psychosocial impacts are crucial for ethical NBS implementation.
• The potential benefits of early detection for individuals and families must be weighed against the complexities of genetic information disclosure.